Drug intelligence / Profile preview

AVR-001

Development stage: Unknown
Lead developer: Avere Therapeutics
Modality: Peptides
Administration: Oral

Overview

AVR-001 is an orally administered peptide antagonist of the interleukin-23 receptor (IL-23R), developed by Avere Therapeutics. By binding to the IL-23 receptor, the drug inhibits IL-23-mediated signaling, a key pathway in the pathogenesis of various autoimmune and inflammatory diseases. AVR-001 is designed to provide the efficacy of injectable biologics with the convenience of oral administration. It has completed Phase 1 multiple ascending dose (MAD) studies and is being developed for the treatment of plaque psoriasis, ulcerative colitis, Crohn's disease, and psoriatic arthritis.

Targets

IL23R (Interleukin-23 Receptor)

Beyond the preview

Go deeper on AVR-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AVR-001.

Explore the full profile